Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
CC transcript
|
|
Synaptogenix, Inc. (SNPX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/10/2020 |
8-K
| Appointed a new director|
Docs:
|
"Amended and Restated Articles of Incorporation of Synaptogenix, Inc.",
"Bylaws of Synaptogenix, Inc",
"Separation and Distribution Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"Tax Matters Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"SEPARATION AGREEMENT",
"Dr. Alan J. Tuchman",
"SYNAPTOGENIX, INC. 2020 EQUITY INCENTIVE PLAN 1. DEFINITIONS.",
"STOCK OPTION AGREEMENT - INCORPORATED TERMS AND CONDITIONS",
"Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for Alzheimer's disease and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual ..." |
|
|
|